0R9T.LSE Equasens
- Market cap
- EUR 581M
- P/E
- 10.5x
- P/B
- -
- ROE
- 30.4%
- Dividend yield
- 2.60%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0R9T.LSE undervalued?
Graham numberThe Graham number of Equasens cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Equasens fundamental analysis
No fundamental analysis for Equasens yet.
Equasens stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Equasens
Equasens Société anonyme provides healthcare IT solutions in France, Italy, Belgium, Germany, the United Kingdom, and internationally. The company operates through Sales of Configurations and Hardware, Maintenance Services and Subscriptions, and Software and Services segments. The company engages in publishing and distribution of pharmacy, practice, management software and related offerings for pharmacies, medical-social establishments, doctors, and medical auxiliaries; dist…
Full company profileEquasens financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Equasens annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 128M | 130M | 148M | 159M | 172M | 193M | 214M | 220M | 217M | 237M | 498M |
| Gross Profit | 37.9M | 37.3M | 42.0M | 44.5M | 49.4M | 53.8M | 59.0M | 56.7M | 47.1M | 49.8M | 100M |
| Operating Income | 31.4M | 34.3M | 38.9M | 40.8M | 46.7M | 50.3M | 56.2M | 55.4M | 44.6M | 47.7M | 93.6M |
| EBITDA | 34.9M | 38.5M | 44.1M | 48.3M | 55.7M | 61.6M | 68.5M | 68.6M | 59.4M | 65.3M | 132M |
| Net Income | 20.6M | 23.2M | 25.4M | 28.4M | 30.7M | 39.1M | 46.2M | 47.0M | 36.2M | 39.3M | 75.9M |
| EPS | 1.36 | 1.55 | 1.70 | 1.89 | 2.04 | 2.58 | 3.05 | 3.10 | 2.39 | 2.62 | 4.81 |
| Balance Sheet | |||||||||||
| Total Assets | 151M | 178M | 224M | 258M | 296M | 330M | 400M | 394M | 398M | 439M | 451M |
| Total Liabilities | 47.0M | 73.2M | 107M | 126M | 147M | 165M | 154M | 166M | 157M | 176M | 190M |
| Shareholders' Equity | 23.6K | 26.2K | 28.5K | 35.9K | 37.5K | 50.5K | 190M | 252M | 232M | 252M | 250M |
| Cash & Short-term Investments | 64.5K | 55.7M | 61.3M | 24.2K | 37.4K | 41.4K | 77.6M | 62.8M | 57.3M | 87.1M | 69.0M |
| Total Debt | 10.4M | 16.9M | 43.2M | 57.5M | 71.8M | 84.1M | 66.7M | 69.3M | 58.5M | 53.9M | 57.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 23.9M | 28.6M | 29.6M | 42.6M | 48.5M | 48.4M | 58.6M | 61.6M | 52.5M | 60.7M | 67.0M |
| Capital Expenditure | 6.02M | 7.70M | 11.1M | 17.0M | 19.7M | 10.4M | 10.2M | 18.4M | 3.03M | 1.87M | 26.7M |
| Free Cash Flow | 17.9M | 20.9M | 18.6M | 25.6M | 28.9M | 38.0M | 48.4M | 43.2M | 49.5M | 58.8M | 40.3M |
| Ratios | |||||||||||
| ROE | 87,140.9% | 88,429.7% | 89,338.5% | 79,064.1% | 81,871.3% | 77,441.9% | 24.4% | 18.7% | 15.7% | 15.6% | 30.4% |
| ROA | 13.6% | 13.0% | 11.4% | 11.0% | 10.4% | 11.9% | 11.6% | 11.9% | 9.1% | 9.0% | 16.8% |
| Net Profit Margin | 16.0% | 17.9% | 17.1% | 17.9% | 17.9% | 20.3% | 21.6% | 21.4% | 16.7% | 16.6% | 15.2% |
| Debt to Equity | 440.73x | 643.44x | 1,517.13x | 1,599.93x | 1,914.27x | 1,664.11x | 0.35x | 0.28x | 0.25x | 0.21x | 0.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Equasens dividends
- Dividend yield
- 2.60%
- Forward dividend
- -
- Payout ratio
- 47.8%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 18.8M | 1.25 | 47.8% |
| 2024 | EUR 18.8M | 1.24 | 51.9% |
| 2023 | EUR 17.3M | 1.14 | 36.7% |
| 2022 | EUR 15.8M | 1.04 | 34.1% |
| 2021 | EUR 14.3M | 0.94 | 36.5% |
| 2020 | EUR 13.5M | 0.90 | 44.1% |
| 2019 | EUR 12.8M | 0.85 | 44.9% |
| 2018 | EUR 11.2M | 0.75 | 44.1% |
| 2017 | EUR 9.73M | 0.65 | 42.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Aug 5, 2015.
Who owns Equasens
- Insiders 67.09%
- Institutions 11.76%
- Public & others 21.16%
- Shares outstanding 15.0M
- Free float 15.0M
Equasens company profile
- Company name
- Equasens
- Ticker
- 0R9T.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 1,500
- Fiscal year end
- December
- Address
- 5 Allée de Saint-Cloud, Villers-lès-Nancy, France, 54600
- Phone
- 33 3 83 15 95 95
- Website
- equasens.com
About Equasens
Equasens Société anonyme provides healthcare IT solutions in France, Italy, Belgium, Germany, the United Kingdom, and internationally. The company operates through Sales of Configurations and Hardware, Maintenance Services and Subscriptions, and Software and Services segments. The company engages in publishing and distribution of pharmacy, practice, management software and related offerings for pharmacies, medical-social establishments, doctors, and medical auxiliaries; distribution of computer equipment, turnkey installation and training; after-sales services, and telephone support and maintenance; and data backup, intermediation, and vocational training services. It also provides medical remote monitoring systems, develops a structured medical speech recognition solution, and designs and manufactures connected electronic devices and equipment, as well as offers interoperability solutions. In addition, the company offers financing platform to facilitate multi-donor management, and financing solutions for leased assets for healthcare professionals and others. It serves healthcare facilities and healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-lès-Nancy, France. Equasens Société anonyme operates as a subsidiary of Marque Verte Sante.
Equasens management
8- Mr. Denis SupplissonCEO & Director · born 1969
- Mr. Grégoire De RotalierDeputy CEO, Deputy MD, Director of Healthcare, Medical & Social Software Division and Director · born 1970
- Mr. Dominique PautratChairman of the Board · born 1965
- Ms. Frederique SchmidtGroup Chief Administrative & Financial Officer
- Ms. Noelle StouligHead of Communications
- Ms. Sabrina GharbiChief Human Resources Officer
- Mr. Dominique GoursaudHead of the Medical Solutions Division
- Mr. Francois-Pierre MarquierDeputy CEO, Director of Pharmagest Division & Director